599 related articles for article (PubMed ID: 30631325)
1. Cytotoxic Pathways in Allogeneic Hematopoietic Cell Transplantation.
Du W; Cao X
Front Immunol; 2018; 9():2979. PubMed ID: 30631325
[TBL] [Abstract][Full Text] [Related]
2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
3. The complex and central role of interferon-γ in graft-versus-host disease and graft-versus-tumor activity.
Wang H; Yang YG
Immunol Rev; 2014 Mar; 258(1):30-44. PubMed ID: 24517424
[TBL] [Abstract][Full Text] [Related]
4. Separation of graft-vs.-tumor effects from graft-vs.-host disease in allogeneic hematopoietic cell transplantation.
Rezvani AR; Storb RF
J Autoimmun; 2008 May; 30(3):172-9. PubMed ID: 18242060
[TBL] [Abstract][Full Text] [Related]
5. Graft-vs.-lymphoma effect in an allogeneic hematopoietic stem cell transplantation model.
Ito M; Shizuru JA
Biol Blood Marrow Transplant; 1999; 5(6):357-68. PubMed ID: 10595813
[TBL] [Abstract][Full Text] [Related]
6. The Role of Co-stimulatory/Co-inhibitory Signals in Graft-vs.-Host Disease.
Kumar S; Leigh ND; Cao X
Front Immunol; 2018; 9():3003. PubMed ID: 30627129
[TBL] [Abstract][Full Text] [Related]
7. Modulation of allogeneic CD8+ T-cell response by DZNep controls GVHD while preserving hematopoietic chimerism.
Wang J; Li L; Xu M; Rong R; Zhu T
Transplantation; 2013 Nov; 96(9):774-81. PubMed ID: 23900211
[TBL] [Abstract][Full Text] [Related]
8. Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma.
Fowler DH; Gress RE
Leuk Lymphoma; 2000 Jul; 38(3-4):221-34. PubMed ID: 10830730
[TBL] [Abstract][Full Text] [Related]
9. Mitochondrial Deacetylase SIRT3 Plays an Important Role in Donor T Cell Responses after Experimental Allogeneic Hematopoietic Transplantation.
Toubai T; Tamaki H; Peltier DC; Rossi C; Oravecz-Wilson K; Liu C; Zajac C; Wu J; Sun Y; Fujiwara H; Henig I; Kim S; Lombard DB; Reddy P
J Immunol; 2018 Dec; 201(11):3443-3455. PubMed ID: 30389773
[TBL] [Abstract][Full Text] [Related]
10. Increased immune transcript levels are correlated with acute graft-versus-host disease and cytomegalovirus response after allogeneic stem cell transplantation.
Jaksch M; Remberger M; Mattsson J
Transplantation; 2004 Jan; 77(2):195-200. PubMed ID: 14742980
[TBL] [Abstract][Full Text] [Related]
11. Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graft-versus-host disease and graft-versus-leukemia effect.
Schmaltz C; Alpdogan O; Horndasch KJ; Muriglan SJ; Kappel BJ; Teshima T; Ferrara JL; Burakoff SJ; van den Brink MR
Blood; 2001 May; 97(9):2886-95. PubMed ID: 11313285
[TBL] [Abstract][Full Text] [Related]
12. T Cell Subsets in Graft Versus Host Disease and Graft Versus Tumor.
Jiang H; Fu D; Bidgoli A; Paczesny S
Front Immunol; 2021; 12():761448. PubMed ID: 34675938
[TBL] [Abstract][Full Text] [Related]
13. Graft-versus-leukemia effect and graft-versus-host disease can be differentiated by cytotoxic mechanisms in a murine model of allogeneic bone marrow transplantation.
Tsukada N; Kobata T; Aizawa Y; Yagita H; Okumura K
Blood; 1999 Apr; 93(8):2738-47. PubMed ID: 10194454
[TBL] [Abstract][Full Text] [Related]
14. Harnessing dendritic cells to improve allogeneic hematopoietic cell transplantation outcome.
Hashimoto D; Merad M
Semin Immunol; 2011 Feb; 23(1):50-7. PubMed ID: 21316261
[TBL] [Abstract][Full Text] [Related]
15. Graft-versus-host disease after allogeneic hematopoietic stem cell transplantation induces a CD8+ T cell-mediated graft-versus-tumor effect that is independent of the recognition of alloantigenic tumor targets.
Stelljes M; Strothotte R; Pauels HG; Poremba C; Milse M; Specht C; Albring J; Bisping G; Scheffold C; Kammertoens T; Oelmann E; Silling G; Berdel WE; Kienast J
Blood; 2004 Aug; 104(4):1210-6. PubMed ID: 15090450
[TBL] [Abstract][Full Text] [Related]
16. Dissecting the biology of allogeneic HSCT to enhance the GvT effect whilst minimizing GvHD.
Blazar BR; Hill GR; Murphy WJ
Nat Rev Clin Oncol; 2020 Aug; 17(8):475-492. PubMed ID: 32313224
[TBL] [Abstract][Full Text] [Related]
17. IFN-gamma and Fas ligand are required for graft-versus-tumor activity against renal cell carcinoma in the absence of lethal graft-versus-host disease.
Ramirez-Montagut T; Chow A; Kochman AA; Smith OM; Suh D; Sindhi H; Lu S; Borsotti C; Grubin J; Patel N; Terwey TH; Kim TD; Heller G; Murphy GF; Liu C; Alpdogan O; van den Brink MR
J Immunol; 2007 Aug; 179(3):1669-80. PubMed ID: 17641033
[TBL] [Abstract][Full Text] [Related]
18. Perforin/granzyme-dependent and independent mechanisms are both important for the development of graft-versus-host disease after murine bone marrow transplantation.
Graubert TA; DiPersio JF; Russell JH; Ley TJ
J Clin Invest; 1997 Aug; 100(4):904-11. PubMed ID: 9259590
[TBL] [Abstract][Full Text] [Related]
19. Ceacam1 separates graft-versus-host-disease from graft-versus-tumor activity after experimental allogeneic bone marrow transplantation.
Lu SX; Kappel LW; Charbonneau-Allard AM; Atallah R; Holland AM; Turbide C; Hubbard VM; Rotolo JA; Smith M; Suh D; King C; Rao UK; Yim N; Bautista JL; Jenq RR; Penack O; Na IK; Liu C; Murphy G; Alpdogan O; Blumberg RS; Macian F; Holmes KV; Beauchemin N; van den Brink MR
PLoS One; 2011; 6(7):e21611. PubMed ID: 21760897
[TBL] [Abstract][Full Text] [Related]
20. NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects.
Olson JA; Leveson-Gower DB; Gill S; Baker J; Beilhack A; Negrin RS
Blood; 2010 May; 115(21):4293-301. PubMed ID: 20233969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
